Sign in
BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Updates from the Field
2019
Real World Patient and Clinical Characteristics in Treatment Naive Neovascular Age-Related Macular Degeneration
Matthew P. Ohr, MD
On Demand Cases, Courses, and Papers
Apples and Oranges: "Real-World" Outcomes Differ From Clinical Trial Outcomes Because "Real-World" Patients Differ From Clinical Trial Patients
Franco M. Recchia, MD
Annual Meeting Talks
2021
Category: AMD-Neovascular